CN105451718B - 微乳剂局部递送平台 - Google Patents

微乳剂局部递送平台 Download PDF

Info

Publication number
CN105451718B
CN105451718B CN201480027477.7A CN201480027477A CN105451718B CN 105451718 B CN105451718 B CN 105451718B CN 201480027477 A CN201480027477 A CN 201480027477A CN 105451718 B CN105451718 B CN 105451718B
Authority
CN
China
Prior art keywords
oil
eye
pharmaceutical composition
surfactant
api
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480027477.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105451718A (zh
Inventor
R.A.瓦塞尔
F.G.蒙达勒克
R.A.法尔霍
A.B.奎安保
D.J.努诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EYECRO LLC
Original Assignee
EYECRO LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EYECRO LLC filed Critical EYECRO LLC
Publication of CN105451718A publication Critical patent/CN105451718A/zh
Application granted granted Critical
Publication of CN105451718B publication Critical patent/CN105451718B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201480027477.7A 2013-03-14 2014-03-13 微乳剂局部递送平台 Active CN105451718B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784005P 2013-03-14 2013-03-14
US61/784005 2013-03-14
PCT/US2014/025773 WO2014160079A1 (en) 2013-03-14 2014-03-13 Microemulsion topical delivery platform

Publications (2)

Publication Number Publication Date
CN105451718A CN105451718A (zh) 2016-03-30
CN105451718B true CN105451718B (zh) 2018-09-28

Family

ID=50628949

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027477.7A Active CN105451718B (zh) 2013-03-14 2014-03-13 微乳剂局部递送平台

Country Status (12)

Country Link
US (2) US8968775B2 (enExample)
EP (1) EP2968139B1 (enExample)
JP (1) JP6348567B2 (enExample)
CN (1) CN105451718B (enExample)
AU (1) AU2014244154B2 (enExample)
CA (1) CA2905023C (enExample)
DK (1) DK2968139T3 (enExample)
ES (1) ES2673009T3 (enExample)
PL (1) PL2968139T3 (enExample)
PT (1) PT2968139T (enExample)
TR (1) TR201808197T4 (enExample)
WO (1) WO2014160079A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374812B1 (en) 2006-07-13 2015-04-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication
ES2584534B1 (es) * 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
EP3405183A4 (en) 2016-01-18 2019-12-11 Arisan Therapeutics Inc. ADAMATE DERIVATIVES FOR TREATING A FILOVIRUS INFECTION
LT3266446T (lt) * 2016-07-07 2019-01-25 Laboratorios Salvat, S.A. Oftalmologinė kompozicija, apimanti ricinos aliejų ir vidutinio grandinės ilgio trigliceridą
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
IL272601B2 (en) * 2017-08-27 2025-03-01 Rhodes Tech Inc Pharmaceutical compositions for the treatment of ophthalmic conditions
US11583497B2 (en) 2017-11-14 2023-02-21 The Schepens Eye Research Institute, Inc. Nano-emulsion of CBFß-RUNX1 inhibitor for ocular drug delivery
JP7569336B2 (ja) 2019-06-11 2024-10-17 サイファイ エス．ピー．エー． マイクロエマルション組成物
WO2021005676A1 (ja) * 2019-07-08 2021-01-14 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用
US20240415796A1 (en) * 2020-11-19 2024-12-19 Nihon University Eyedrops for ameliorating or preventing retinal circulation disorder and retinal neurovascular coupling disorder
CN119789854A (zh) * 2023-08-04 2025-04-08 Ads医疗有限责任公司 用于递送眼科活性物的组合物和方法
WO2025090133A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058316B2 (en) * 2007-09-24 2011-11-15 Charlesson, Llc STAT3 inhibiting compositions and methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398261B (zh) * 2003-12-17 2013-06-11 Alcon Inc 血清類澱粉ａ基因於診斷及治療青光眼及鑑定抗青光眼劑上之用途
US7569612B1 (en) * 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
CA2827082A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058316B2 (en) * 2007-09-24 2011-11-15 Charlesson, Llc STAT3 inhibiting compositions and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNA RADOMSKA-SOUKHAREV, et.al.MICROEMULSIONS AS POTENTIAL OCULAR DRUG DELIVERY SYSTEMS: PHASE DIAGRAMS AND PHYSICAL PROPERTIES DEPENDING ON INGREDIENTS.《Acta Poloniae Pharmaceutica》.2005,第62卷(第6期), *
MICROEMULSIONS AS POTENTIAL OCULAR DRUG DELIVERY SYSTEMS: PHASE DIAGRAMS AND PHYSICAL PROPERTIES DEPENDING ON INGREDIENTS;ANNA RADOMSKA-SOUKHAREV, et.al;《Acta Poloniae Pharmaceutica》;20051231;第62卷(第6期);第467页左栏"Preparation of microemulsions"部分；第467页表1处方D；第470页右栏第2段 *
Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride;Hussein O. Ammar,et.al;《AAPS PharmSciTech》;20090930;第10卷(第3期);第808-819页 *

Also Published As

Publication number Publication date
JP2016512562A (ja) 2016-04-28
CN105451718A (zh) 2016-03-30
EP2968139A1 (en) 2016-01-20
TR201808197T4 (tr) 2018-07-23
US8968775B2 (en) 2015-03-03
AU2014244154A1 (en) 2015-09-24
AU2014244154B2 (en) 2018-08-09
PL2968139T3 (pl) 2018-10-31
WO2014160079A1 (en) 2014-10-02
US9149453B2 (en) 2015-10-06
EP2968139B1 (en) 2018-05-23
JP6348567B2 (ja) 2018-06-27
DK2968139T3 (en) 2018-06-25
CA2905023C (en) 2019-10-15
ES2673009T3 (es) 2018-06-19
CA2905023A1 (en) 2014-10-02
PT2968139T (pt) 2018-06-18
US20140275263A1 (en) 2014-09-18
US20150164846A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
CN105451718B (zh) 微乳剂局部递送平台
US20240307306A1 (en) Microemulsion for ophthalmic drug delivery
AU2008310956B2 (en) Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
JP2016512562A5 (enExample)
CN103533962B (zh) 一种眼用组合物
JP7547411B2 (ja) 局所用シクロスポリン含有製剤およびその使用
JP7496778B2 (ja) チモロールを含む医薬組成物
CN112135603B (zh) 包含奈必洛尔的药物组合物
JP6824270B2 (ja) 生物活性親油性化合物を有するｐｅｇ化脂質ナノ粒子
JPH0899867A (ja) 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法
CN103764120A (zh) 聚乙二醇15羟基硬脂酸酯制剂
KR20150000405A (ko) 난용성 의약품의 수중유적형 에멀젼 조성물 및 이의 제조방법
Lallemand et al. Emulsions for topical eye delivery: state of the art and future perspectives
CN112891312B (zh) 含有榄香烯的药物组合物及其制备方法和用途
Khan et al. Self-Nano Emulsifying Drug delivery system (SNEEDS) for Ocular Administration
Acharya Development and Evaluation of Liquid Crystalline Cubogel for Ocular Delivery of Anti-glaucoma Agents
US20140302099A1 (en) Ophthalmic Composition Containing Cyclosporine And method For Preparing Same
Ramesh Ocular barriers and ocular drug delivery: Bridging the gap using nanomicelles as drug carriers
Khodakiya Formulation Design and Optimization of topical Microemulsion in Situ Gelling System: Drug Delivery to Posterior Segment of the Eye
HK40044057B (zh) 包含奈必洛尔的药物组合物
HK40044057A (en) Pharmaceutical compositions comprising nebivolol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant